首页> 外文期刊>Clinical & translational immunology. >Associations of pathogen‐specific and host‐specific characteristics with disease outcome in patients with Staphylococcus aureus bacteremic pneumonia
【24h】

Associations of pathogen‐specific and host‐specific characteristics with disease outcome in patients with Staphylococcus aureus bacteremic pneumonia

机译:金黄色葡萄球菌细菌性肺炎患者病原体特异性和宿主特异性特征与疾病结局的关系

获取原文
           

摘要

Objective To understand the relationships of Staphylococcus aureus (SA) bacteremic pneumonia (SABP) outcome with patient‐specific and SA‐specific variables. Methods We analysed SA bloodstream isolates and matching sera in SABP patients by sequencing SA isolates ( n =?50) and measuring in?vitro AT production, haemolytic activity and expression of ClfA and ClfB. Controls were sera from gram‐negative bacteremia patients with or without pneumonia and uninfected subjects. Levels of IgGs, IgMs and neutralizing antibodies (NAbs) against SA antigens were quantified and analysed by one‐way ANOVA. Associations of patient outcomes with patient variables, antibody levels and isolate characteristics were evaluated by univariate and multivariate logistic regression analyses. Results SABP patients had higher levels of IgGs against eight virulence factors and anti‐alpha toxin (AT) NAbs than uninfected controls. Levels of IgG against AT and IgMs against ClfA, FnbpA and SdrC were higher in clinically cured SABP patients than in clinical failures. Anti‐LukAB NAb levels were elevated in all cohorts. Increased odds of cure correlated with higher haemolytic activity of SA strains, longer time between surgery and bacteremia (?30?days), longer duration of antibiotic therapy, lower acute physiology and total APACHE II scores, lack of persistent fever for ?72?h and higher levels of antibodies against AT (IgG), ClfA (IgM), FnbpA (IgM) and SdrC (IgM). Discussion Limitations included the cross‐sectional observational nature of the study, small sample size and inability to measure antibody levels against all SA virulence factors. Conclusion Our results suggest that SABP patients may benefit from immunotherapy targeting multiple SA antigens.
机译:目的了解金黄色葡萄球菌(SA)细菌性肺炎(SABP)结局与患者特异性和SA特异性变量之间的关系。方法我们通过对SABP患者的SA分离株(n = 50)进行测序,并测定其体外AT的产生,溶血活性以及ClfA和ClfB的表达,分析SABP患者的SA血流分离株和匹配血清。对照是来自有或没有肺炎的革兰氏阴性菌血症患者和未感染受试者的血清。通过单向方差分析对SA抗原的IgG,IgM和中和抗体(NAb)的水平进行定量和分析。通过单因素和多因素logistic回归分析评估患者预后与患者变量,抗体水平和分离株特征之间的关系。结果SABP患者抗八种毒力因子和抗α毒素(AT)NAb的IgG水平高于未感染的对照组。临床治愈的SABP患者抗AT的IgG水平和抗ClfA,FnbpA和SdrC的IgMs水平均高于临床失败者。在所有队列中,抗-LukAB NAb水平均升高。治愈几率的增加与SA菌株的溶血活性更高,手术和菌血症之间的时间更长(>?30?days),抗生素治疗的时间更长,急性生理机能降低以及APACHE II总评分较低,≥72的持续性发热无关。 ?h和更高水平的抗AT(IgG),ClfA(IgM),FnbpA(IgM)和SdrC(IgM)抗体。讨论的局限性包括研究的横断面观察性质,样本量小以及无法测量针对所有SA毒力因子的抗体水平。结论我们的结果表明SABP患者可从针对多种SA抗原的免疫疗法中受益。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号